Pharma Codevelopment Soaring, FDA Guidance Stalling

January 9, 2013
A new report by healthcare investment bank Leerink Swann trumpets the benefits of codevelopment partnerships and acquisitions (P&A): improved market performance, reduced R&D inefficiencies and healthy product pipelines. The number of biopharma acquisitions in 2012 (nine) surpassed 2011 (six) and that trend is likely to continue as companies have spent less in aggregate on P&A over time, the report states.
Washington Drug Letter